Cargando…
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model
BACKGROUND: Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical studies often do not use these regimens, since adm...
Autores principales: | Delahoussaye, Abagail M., Abi Jaoude, Joseph, Green, Morgan, Fujimoto, Tara N., Molkentine, Jessica, Garcia Garcia, Carolina J., Gay, Jason P., Feng, Ningping, Marszalek, Joseph, Fowlkes, Natalie, Taniguchi, Cullen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848646/ https://www.ncbi.nlm.nih.gov/pubmed/35172762 http://dx.doi.org/10.1186/s12885-022-09255-3 |
Ejemplares similares
-
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment
por: Garcia Garcia, Carolina J., et al.
Publicado: (2022) -
Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy
por: Kouzy, Ramez, et al.
Publicado: (2020) -
Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer
por: Nguyen, Nicholas D., et al.
Publicado: (2021) -
Cancer Research after COVID-19: Where Do We Go from Here?
por: Colbert, Lauren E., et al.
Publicado: (2020) -
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era
por: Abi Jaoude, Joseph, et al.
Publicado: (2021)